New York State Common Retirement Fund Boosts Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

New York State Common Retirement Fund increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 11.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 53,688 shares of the company’s stock after acquiring an additional 5,361 shares during the period. New York State Common Retirement Fund owned about 0.11% of Amphastar Pharmaceuticals worth $3,321,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock worth $1,326,000 after purchasing an additional 169 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Amphastar Pharmaceuticals by 1.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock worth $1,262,000 after buying an additional 358 shares during the last quarter. McGlone Suttner Wealth Management Inc. purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth approximately $28,000. Teacher Retirement System of Texas grew its position in Amphastar Pharmaceuticals by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 10,967 shares of the company’s stock valued at $504,000 after acquiring an additional 507 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Amphastar Pharmaceuticals by 99.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after acquiring an additional 628 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

AMPH has been the subject of a number of research reports. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $66.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 14,000 shares of company stock valued at $655,145 in the last 90 days. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 0.5 %

NASDAQ:AMPH opened at $42.46 on Monday. The firm has a market capitalization of $2.04 billion, a P/E ratio of 16.46, a P/E/G ratio of 1.02 and a beta of 0.85. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The company has a fifty day moving average of $43.48 and a 200 day moving average of $50.78. Amphastar Pharmaceuticals, Inc. has a 52 week low of $35.93 and a 52 week high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). The firm had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. On average, research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.